Current stock page

Financial Data

MIRM Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

MIRMMirum Pharmaceuticals, Inc.

Healthcare / Biotechnology

Low Priority

In Line With Peers

NeutralEdge 5/10
$93.99+$0.66 (+0.71%)

Latest quote

  • Momentum
    54
  • Value
    57
  • Quality
    52
  • Risk resilience
    51
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$185.72M$176.24M$159.88M$148.93M$133.01M$127.79M$111.59M$99.41M
Gross Profit$150.55M$145.9M$131M$120.59M$107.47M$104.36M$88.57M$76.63M
Operating Income-$59.75M-$42.54M-$63.16M-$4.57M$2.6M-$4.99M-$15.18M-$24.22M
Net Income-$40.77M-$67.23M-$790.16M-$5.73M$2.91M-$5.86M-$14.68M-$23.79M
EPS-$0.62-$1.06-$13.43-$0.12$0.05-$0.12-$0.3-$0.49
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$4.31M-$273.02M-$228.76M$6.07M$39.68M$12.04M-$1.96M-$5.07M
Capital Expenditure-$1.31M-$687K-$664K-$600K-$187K-$126K-$41K-$20K
Free Cash Flow-$5.62M-$273.7M-$229.43M$5.47M$39.49M$11.91M-$2M-$5.09M
Net Cash Provided By Operating Activities-$4.31M-$273.02M-$228.76M$6.07M$39.68M$12.04M-$1.96M-$5.07M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$1.03B$1.04B$890.92M$842.81M$785.12M$725.83M$690.25M$670.75M
Total Debt$743.56M$760.54M$323.78M$319.45M$318.76M$318.9M$317.16M$317.76M
Cash And Cash Equivalents$243.19M$330.73M$324.91M$296.68M$282.02M$228.12M$211.82M$222.5M
Total Liabilities$1.08B$1.06B$648.42M$528.12M$493.07M$470.67M$456.99M$445.11M
Total Stockholders Equity-$54.19M-$10.42M$242.49M$314.69M$292.05M$255.16M$233.26M$225.64M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio——26.7217.3313.8510.48.6410.82
P/S ratio9.18———————
Debt To Equity——1.341.021.091.251.361.41
Free Cash Flow Yield-8.13%-6.83%-2.66%1.01%1.10%-0.05%-1.38%-0.44%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio——26.7217.3313.8510.48.6410.82
P/S ratio9.18———————
Return On Equity——-3.29%-7.42%-14.18%-22.95%-33.16%-38.97%
Debt To Equity——1.341.021.091.251.361.41

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-6.17x
Pb-113.66x
Revenue Growth Yoy39.63%
EPS Growth Yoy-1315.69%
Gross Margin81.70%
Operating Margin-25.35%
ROE-734.00%
ROIC-22.79%
Debt To Equity-13.72
FCF Yield-8.20%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$93.99
Volume331,057
RSI (14)59.88
MACD2.13
MACD signal1.16
MACD histogram0.97
ADX (14)26.11
SMA (50)$88.79
SMA (200)$98.41
ATR (14)$3.95
Historical volatility (annualized)50.58%
Volume (20-day average)609,764

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score51/100
Beta1.07
Annual volatility48.60%
Max Drawdown-38.36%
Sharpe Ratio0.79
VaR (95%, 1-day)-4.94%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

MIRM Financial Data FAQ

What is Mirum Pharmaceuticals, Inc.'s revenue?

Mirum Pharmaceuticals, Inc.'s revenue is one of the core financial data points for MIRM. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Mirum Pharmaceuticals, Inc.'s revenue growing?

Revenue growth shows whether Mirum Pharmaceuticals, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is MIRM's EPS?

MIRM's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Mirum Pharmaceuticals, Inc.'s net income?

Mirum Pharmaceuticals, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Mirum Pharmaceuticals, Inc. generate?

Free cash flow shows how much cash Mirum Pharmaceuticals, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Mirum Pharmaceuticals, Inc. have?

Cash and debt help frame MIRM's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.